Novel Peptides Mimicking GLP-1 Action Discovered from Antibody Library
Background
Glucagon-like peptide-1 (GLP-1) is a crucial hormone involved in glucose homeostasis, stimulating insulin secretion and promoting satiety. GLP-1 receptor agonists are highly effective treatments for type 2 diabetes and obesity, but current peptide-based drugs can have limitations regarding stability, administration, and cost. This study aimed to identify novel, smaller peptide sequences, known as mimotopes, that could mimic GLP-1's therapeutic actions by binding to and activating its receptor.
Results
The high-throughput screening successfully identified several novel GLP-1 mimotopes with significant GLP-1R binding capabilities. GM-1 demonstrated a potent GLP-1R binding affinity with an IC50 of 15 nM, which was 2.5-fold stronger than that of native GLP-1(7-36) amide (IC50 = 37.5 nM) in competitive binding assays. Both GM-1 and GM-2 significantly activated cAMP (cyclic adenosine monophosphate, a key intracellular signaling molecule) production in GLP-1R-expressing cells, with GM-1 showing a 3.2-fold increase over baseline at 100 nM, comparable to native GLP-1. Furthermore, GM-1 stimulated insulin secretion from isolated pancreatic islets by 43% compared to control at 50 nM, indicating robust functional agonism in vitro.
Why It Matters
This discovery of novel GLP-1 mimotopes represents a significant step forward in the development of new therapeutic agents for type 2 diabetes and obesity. These smaller, potentially more stable, and easier-to-manufacture peptides could lead to improved drug formulations with better pharmacokinetics, reduced side effects, and lower production costs compared to existing GLP-1 agonists. The next critical steps involve comprehensive in vivo studies to evaluate the efficacy, safety, and pharmacokinetics of these mimotopes in animal models, paving the way for potential human clinical trials.